102.07

0.68% 0.69

Guardant Health Inc (GH)

Overview News Price History Option Chain Financials Why GH Down? Discussions Forecast

Guardant Health Inc stock is traded at $102.07, with a volume of 1.49M. It is up +0.68% in the last 24 hours and up +4.32% over the past month. Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Previous Close:

$101.38

Open:

$103.52

24h Volume:

1.49M

Relative Volume:

0.57

Market Cap:

$13.26B

Revenue:

$692.26M

Net Income/Loss:

$-512.41M

P/E Ratio:

-24.07

EPS:

-4.24

Net Cash Flow:

$-274.36M

1W Performance:

+0.05%

1M Performance:

+4.32%

6M Performance:

+108.22%

1Y Performance:

+192.13%

1-Day Range:

$100.47

$103.52

1-Week Range:

$100.21

$106.15

52-Week Range:

$29.91

$112.42

Guardant Health Inc Stock (GH) Company Profile

Name

Guardant Health Inc

Sector

Healthcare (1123)

Industry

Diagnostics & Research (53)

Phone

855-698-8887

Address

3100 HANOVER STREET, PALO ALTO

Employee

2,021

Twitter

@guardanthealth

Next Earnings Date

2024-11-06

Latest SEC Filings

GH's Discussions on Twitter

Compare GH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GH Guardant Health Inc	102.07	13.17B	692.26M	-512.41M	-274.36M	-4.24
TMO Thermo Fisher Scientific Inc	572.28	217.50B	43.74B	6.58B	6.11B	17.31
DHR Danaher Corp	226.33	164.13B	24.27B	3.50B	5.02B	4.8589
IDXX Idexx Laboratories Inc	704.20	56.49B	4.17B	1.03B	940.22M	12.61
A Agilent Technologies Inc	139.68	40.44B	6.95B	1.30B	1.15B	4.5714
IQV Iqvia Holdings Inc	222.26	38.48B	15.90B	1.28B	2.21B	7.2842

Guardant Health Inc Stock (GH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Resumed	Morgan Stanley	Overweight
Sep-25-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Sep-22-25	Resumed	Wells Fargo	Overweight
Apr-10-25	Initiated	Mizuho	Outperform
Jan-23-25	Initiated	Barclays	Overweight
Jun-28-24	Upgrade	Guggenheim	Neutral → Buy
Jun-03-24	Resumed	Jefferies	Buy
Apr-24-24	Resumed	Craig Hallum	Buy
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-13-23	Upgrade	Raymond James	Mkt Perform → Outperform
Sep-28-23	Initiated	Bernstein	Outperform
Sep-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Jul-05-23	Resumed	JP Morgan	Overweight
May-26-23	Upgrade	Citigroup	Neutral → Buy
May-05-23	Initiated	UBS	Buy
Mar-09-23	Downgrade	Citigroup	Buy → Neutral
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Nov-01-22	Downgrade	Piper Sandler	Overweight → Neutral
Oct-19-22	Initiated	Craig Hallum	Buy
Oct-06-22	Initiated	Stephens	Overweight
Aug-25-22	Initiated	Credit Suisse	Outperform
Jun-03-22	Initiated	Piper Sandler	Overweight
Apr-28-22	Resumed	BTIG Research	Buy
Feb-24-22	Reiterated	Canaccord Genuity	Buy
Feb-24-22	Reiterated	Citigroup	Buy
Feb-24-22	Reiterated	Cowen	Outperform
Feb-24-22	Reiterated	Morgan Stanley	Overweight
Feb-24-22	Reiterated	SVB Leerink	Outperform
Feb-24-22	Reiterated	Stifel	Buy
Feb-24-22	Reiterated	Wells Fargo	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Buy
May-25-21	Initiated	Wells Fargo	Overweight
Jan-11-21	Initiated	Stifel	Buy
Sep-09-20	Initiated	Morgan Stanley	Overweight
Jun-12-20	Initiated	BTIG Research	Buy
Feb-21-20	Initiated	Guggenheim	Buy
Jan-07-20	Initiated	Citigroup	Buy
Aug-07-19	Reiterated	Canaccord Genuity	Buy
Apr-16-19	Initiated	Canaccord Genuity	Buy
Apr-10-19	Upgrade	BofA/Merrill	Neutral → Buy
Feb-28-19	Reiterated	BofA/Merrill	Neutral
Oct-29-18	Initiated	BofA/Merrill	Neutral
Oct-29-18	Initiated	JP Morgan	Overweight
Oct-29-18	Initiated	William Blair	Outperform

View All

Guardant Health Inc Stock (GH) Latest News

Dec 12, 2025

GeneDx and Guardant Health named as BTIG’s top picks for 2026 - Investing.com UK

Dec 12, 2025

GH: Analyst Mark Massaro Raises Price Target for Guardant Health | GH Stock News - GuruFocus

Dec 12, 2025

Osterweis Capital Management Inc. Lowers Stock Position in Guardant Health, Inc. $GH - MarketBeat

Dec 12, 2025

Dec 11, 2025

Insider Selling: Guardant Health (NASDAQ:GH) CEO Sells 100,000 Shares of Stock - MarketBeat

Dec 11, 2025

Guardant Health (NASDAQ:GH) Director Sells $131,250.00 in Stock - MarketBeat

Dec 11, 2025

Guardant Health announces proposed $300 million offering of convertible senior notes due 2033 - MSN

Dec 11, 2025

Guardant Health (GH) Jumps to New Record High on Earnings Blowout, Bullish Outlook - MSN

Dec 11, 2025

Citigroup Raises Price Target for GH to $135, Maintains Buy Rati - GuruFocus

Dec 11, 2025

HighVista Strategies LLC Has $1.47 Million Stake in Guardant Health, Inc. $GH - MarketBeat

Dec 11, 2025

Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S. - Business Wire

Dec 11, 2025

Have Guardant Health Insiders Been Selling Stock? - simplywall.st

Dec 11, 2025

Guardant Health Insider Sold Shares Worth $10,505,474, According to a Recent SEC Filing - marketscreener.com

Dec 11, 2025

Guardant Health director Talasaz sells $10.5 million in shares By Investing.com - Investing.com South Africa

Dec 11, 2025

Guardant Health director Talasaz sells $10.5 million in shares - Investing.com

Dec 11, 2025

Dec 10, 2025

Insider Sell: Kumud Kalia Sells 2,000 Shares of Guardant Health Inc (GH) - GuruFocus

Dec 10, 2025